What question did this study set out to answer?

To assess the impact of adjuvant capecitabine on survival outcomes in women with triple-negative breast cancer after neoadjuvant chemotherapy.

April 1, 2026Open Access

Adjuvant capecitabine in women with triple-negative breast cancer with residual disease after carboplatin-containing neoadjuvant chemotherapy

GTGrazielle Morais TavaresUniversidade Estadual de Campinas (UNICAMP)SRSusana RamalhoUniversidade Estadual de Campinas (UNICAMP)LSLeonardo Roberto da SilvaUniversidade Estadual de Campinas (UNICAMP)

Key Points

To assess the impact of adjuvant capecitabine on survival outcomes in women with triple-negative breast cancer after neoadjuvant chemotherapy.
Real-world cohort study design
Focus on women with triple-negative breast cancer
Assessment of pCR as a predictor of prognosis
Evaluation of survival outcomes related to capecitabine
Achieving pCR was a strong indicator of better prognosis.
Adjuvant capecitabine did not show significant survival benefits.
Uncertainty remains regarding capecitabine's role after platinum-based chemotherapy.

Abstract

In this real-world cohort, achieving pCR after carboplatin-containing NACT was the strongest determinant of favorable prognosis. Adjuvant capecitabine was not associated with statistically significant improvement in survival outcomes. The role of capecitabine following prior platinum exposure remains uncertain and warrants further investigation.

AIに質問

Bookmark

View Full Paper